Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Long-term toxicities in paediatric ALL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.01.20
Views: 276

Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark

Prof Kjeld Schmiegelow speaks to ecancer at the 2020 ALL Assembly meeting about the long-term toxicities in paediatric ALL.

He explains that as the cure rate of childhood leukaemia has now reached 90%, the risk of dying from toxicities is now equal to dying from the leukaemia itself.

On top of this, over half of patients that are cured will then be burdened with serious toxicities that affect their quality of life.

Prof Schmiegelow states that a better stratification of patients and understanding patient drug disposition will help improve toxicities in patients.


Related videos

follow us

WIN 2020

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation